Medpace Stock Gains 18% as Q2 Earnings and Bookings Crush Expectations

Medpace Holdings (MEDP) shares surged roughly 18% Wednesday after the contract research organization blew past Wall Street’s second-quarter estimates and posted a sharp rebound in new business. The report vaulted MEDP to the top of the day’s biggest-gainer lists as investors rushed back into the stock.

A Blowout Quarter

Medpace came out swinging in the second quarter of 2026. Revenue climbed 17.2% year over year to $707.3 million, up from $603.3 million a year earlier. Profitability jumped even faster: GAAP net income rose to $121.4 million, or $4.25 per diluted share, compared with $90.3 million, or $3.10 per share, in the prior-year period. As a result, the company’s net income margin widened to 17.2% from 15.0%.

Bookings Come Roaring Back

Beyond the headline beat, the bookings recovery drove much of the enthusiasm. Net new business awards soared 28.2% to $795.7 million, up from $620.5 million a year ago, translating into a healthy net book-to-bill ratio of 1.13x. Consequently, Medpace reversed the softer demand trends that had dogged it earlier in the year — and gave investors fresh confidence in its growth pipeline.

Backlog and Margins Hold Firm

Meanwhile, the underlying business stayed solid. Backlog grew 4.9% to $3.01 billion as of June 30, up from $2.87 billion a year earlier, while the company converted 24.1% of that backlog into revenue during the quarter. EBITDA rose 17.6% to $153.4 million, holding an EBITDA margin of 21.7%. Taken together, these figures show Medpace scaling revenue without sacrificing profitability.

Why It Matters

For investors, the quarter matters because it reframes the CRO demand story. After a shaky first quarter, Medpace demonstrated that pharma and biotech clients are still committing dollars to clinical trials — and that Medpace is winning more of that work. Therefore, the bookings surge serves as a leading indicator that the momentum could carry into future quarters.

The Bottom Line

Ultimately, Medpace delivered exactly what the market wanted: faster revenue growth, expanding margins, and a decisive rebound in new orders. As long as bookings and backlog stay strong, this quarter’s rally may mark the start of a broader turnaround narrative for the stock.